Co­herus' new fo­cus on on­col­o­gy leads to re­struc­tur­ing, 30% lay­offs

Co­herus Bio­Sciences is lay­ing off about 30% of its staff by the end of the year, fol­low­ing its plan to fo­cus on on­col­o­gy and its sale of oph­thal­mol­o­gy biosim­i­lar Cimer­li to San­doz.

In its full-year earn­ings, Co­herus said Wednes­day that a “sharp­ened fo­cus in on­col­o­gy and a sub­se­quent re­struc­tur­ing” would lead to the lay­offs, with about 35 of those po­si­tions linked to the sale of Cimer­li. Co­herus es­ti­mat­ed it will save the com­pa­ny more than $25 mil­lion in an­nu­al­ized cost sav­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER